An Intervention Study of Compound Silymarin in Patients With Non-alcoholic Fatty Liver Disease

NCT ID: NCT05497765 Phase: NA Status: COMPLETED Enrollment: 94 Completion: 2024-02-20

Conditions

Nonalcoholic Fatty Liver Disease

Interventions

Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza, Silibinin extract, Placebo

Summary

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China. The aim of this project is to evaluate the effects of compound silymarin on biomarkers of lipid metabolism and inflammation in the patients with NAFLD.

Primary Outcome

Liver enzymes

Source

ClinicalTrials.gov